Ishara Investments LP Buys Shares of 24,000 Dianthus Therapeutics, Inc. $DNTH

Ishara Investments LP bought a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the fourth quarter, Holdings Channel.com reports. The institutional investor bought 24,000 shares of the company’s stock, valued at approximately $989,000.

Several other hedge funds have also made changes to their positions in DNTH. Raymond James Financial Inc. acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth about $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $40,000. Russell Investments Group Ltd. acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth about $64,000. Tower Research Capital LLC TRC lifted its position in shares of Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after purchasing an additional 3,317 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in shares of Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after purchasing an additional 542 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on DNTH shares. Wedbush increased their price target on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Raymond James Financial reissued a “strong-buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wells Fargo & Company started coverage on shares of Dianthus Therapeutics in a research report on Thursday, March 19th. They set an “overweight” rating and a $135.00 price target on the stock. Stifel Nicolaus set a $120.00 price target on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Finally, TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $117.82.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Ryan Savitz sold 114,367 shares of the stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the transaction, the executive vice president owned 4,000 shares in the company, valued at $362,480. This represents a 86.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 149,121 shares of company stock worth $12,635,454 over the last quarter. 3.02% of the stock is currently owned by insiders.

Dianthus Therapeutics Stock Up 3.8%

Shares of NASDAQ:DNTH opened at $81.89 on Thursday. The firm’s 50 day moving average price is $86.81 and its 200 day moving average price is $66.00. The stock has a market cap of $4.48 billion, a price-to-earnings ratio of -19.83 and a beta of 1.18. Dianthus Therapeutics, Inc. has a fifty-two week low of $16.64 and a fifty-two week high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. The firm had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. On average, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.